Weekly Investment Analysts’ Ratings Updates for Viridian Therapeutics (VRDN)

A number of firms have modified their ratings and price targets on shares of Viridian Therapeutics (NASDAQ: VRDN) recently:

• 5/15/2026 – Viridian Therapeutics was given a new $26.00 price target by Evercore Inc.
• 5/13/2026 – Viridian Therapeutics was given a new $39.00 price target by Stifel Nicolaus.
• 5/9/2026 – Viridian Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
• 5/6/2026 – Viridian Therapeutics had its price target raised by Royal Bank Of Canada from $30.00 to $34.00. They now have an “outperform” rating on the stock.
• 5/5/2026 – Viridian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $32.00 price target on the stock.
• 4/21/2026 – Viridian Therapeutics had its price target lowered by Truist Financial Corporation from $36.00 to $33.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Viridian Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/8/2026 – Viridian Therapeutics had its price target lowered by Wedbush from $37.00 to $31.00. They now have an “outperform” rating on the stock.
• 4/7/2026 – Viridian Therapeutics had its price target lowered by The Goldman Sachs Group, Inc. from $36.00 to $31.00. They now have a “buy” rating on the stock.
• 4/7/2026 – Viridian Therapeutics had its price target lowered by Royal Bank Of Canada from $42.00 to $30.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by The Goldman Sachs Group, Inc. from $41.00 to $36.00. They now have a “buy” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by Wells Fargo & Company from $29.00 to $20.00. They now have an “equal weight” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by Wedbush from $44.00 to $37.00. They now have an “outperform” rating on the stock.
• 3/31/2026 – Viridian Therapeutics had its price target lowered by HC Wainwright from $34.00 to $22.00. They now have a “buy” rating on the stock.
• 3/30/2026 – Viridian Therapeutics had its price target lowered by Needham & Company LLC from $42.00 to $32.00. They now have a “buy” rating on the stock.

Insider Buying and Selling

In other news, Director Fairmount Funds Management Llc bought 1,176,470 shares of the stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $17.00 per share, with a total value of $19,999,990.00. Following the purchase, the director owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This represents a 30.05% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 2.40% of the company’s stock.

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.